Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
80 Leser
Artikel bewerten:
(0)

EQS-News: Shineway worked overtime throughout the Chinese New Year holiday to produce anti-flu medications

Dow Jones received a payment from EQS/DGAP to publish this press release.

EQS-News / 26/02/2018 / 18:22 UTC+8 
 
?*For Immediate Release*? 
 
???????????? 
 
*China Shineway Pharmaceutical Group Limited *(*Stock Code: 2877*) 
 
*Shineway worked overtime throughout the Chinese New Year holiday 
to produce anti-flu medications* 
 
(Hong Kong, 26 February 2018) ---- The largest Chinese medicine injections, 
soft capsules and granules manufacturer in the PRC, *China Shineway 
Pharmaceutical Group Limited* ("Shineway") (HKEx stock code: 2877) today 
told investors in a monthly newsflash the following: 
 
1. To meet the strong demand for anti-flu medications, our production 
workshops did not take time off, but worked overtime throughout the Chinese 
New Year long holiday to make Qingkailing Injection, Qingkailing Soft 
Capsule, Paediatric Qingfei Huatan Granule, TCM Formula Granules etc., in an 
effort to safeguard the public's health. 
 
2. Huamoyan Granule, Dan Deng Tong Nao Capsule, and Qingkailing Soft Capsule 
are Shineway's exclusive oral products included in the National Drug 
Reimbursement List. Shineway will place a heavy focus to nurture each of 
these high growth potential products for three years to reach multi-hundred 
million in sales. Huamoyan Granule is the only synovitis focused innovative 
prescription drugs for osteoarthritis treatment in the country, and can 
effectively resolve anti-inflammatory pain, repair damaged synovium, and 
delay degeneration of cartilage. Dan Deng Tong Nao Capsule is our exclusive 
medicine originated from the Yi tribe for treating stroke caused by blood 
stasis. Its curative effect in the treatment of stroke is highly notable, 
and effectively improve patients' daily living activities during recovery 
period and facilitate restoration of brain functions. Qingkailing Soft 
Capsule is used for nasal congestion, nasal discharge, sore throat, fever 
and other upper respiratory tract symptoms caused by viruses and bacteria. 
It is an effective remedy in curing respiratory tract infections acquired in 
the community. These three exclusive oral products are set to serve as one 
of the catalysts for sales growth. 
 
End 
 
*About China Shineway Pharmaceutical Group Limited (Stock Code: 2877)* 
 
China Shineway Pharmaceutical Group Limited is one of the largest modern 
Chinese medicines manufacturers in the PRC. The Group is listed on the Main 
Board of Hong Kong Stock Exchange and is also a Hang Seng Composite Index 
constituent. 
 
Media Contact: 
 
China Shineway Pharmaceutical Group Limited 
Mr. Randy Hung ¦ Tel: (852) 3521-0816 ¦ randyhung@shineway.com.hk 
 
Document: http://n.eqs.com/c/fncls.ssp?u=RARCIYRPTD [1] 
Document title: Shineway worked overtime throughout the Chinese New Year 
holiday to produce anti-flu medications 
 
26/02/2018 Dissemination of a Marketing Press Release, transmitted by EQS 
Group. 
The issuer is solely responsible for the content of this announcement. 
 
Media archive at www.todayir.com 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5853e8561cd982d88bde9940117118e1&application_id=657635&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

February 26, 2018 05:22 ET (10:22 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.